Sino Biopharmaceutical Ltd
HKEX:1177

Watchlist Manager
Sino Biopharmaceutical Ltd Logo
Sino Biopharmaceutical Ltd
HKEX:1177
Watchlist
Price: 3.33 HKD 1.22%
Market Cap: 61.1B HKD
Have any thoughts about
Sino Biopharmaceutical Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one Sino Biopharmaceutical Ltd stock under the Base Case scenario is 4.26 HKD. Compared to the current market price of 3.33 HKD, Sino Biopharmaceutical Ltd is Undervalued by 22%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
4.26 HKD
Undervaluation 22%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.1
P/S
P/S
Price to Sales
2.1
vs History
71
vs Industry
55
Median 3Y
2.3
Median 5Y
2.8
Industry
2.6
Forward
1.9
More Details
13.9
P/E
P/E
Price to Earnings
13.9
vs History
65
vs Industry
23
Median 3Y
14.8
Median 5Y
22.5
Industry
23
Forward
18.1
More Details
9.4
P/OCF
P/OCF
Price to OCF
9.4
vs History
80
vs Industry
39
Median 3Y
10.7
Median 5Y
12.7
Industry
17.8
More Details
20.1
P/FCFE
P/FCFE
Price to FCFE
20.1
vs History
39
vs Industry
23
Median 3Y
17.3
Median 5Y
18.1
Industry
25.4
More Details
1.7
P/B
P/B
Price to Book Value
1.7
vs History
82
vs Industry
46
Median 3Y
2.1
Median 5Y
2.5
Industry
2.2
More Details
1.7
EV/S
EV/S
Enterprise Value to Sales
1.7
vs History
69
vs Industry
66
Median 3Y
1.8
Median 5Y
2.3
Industry
2.8
Forward
1.5
More Details
2
EV/GP
EV/GP
Enterprise Value to Gross Profit
2
vs History
71
vs Industry
76
Median 3Y
2.1
Median 5Y
2.8
Industry
5.4
More Details
6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
6
vs History
82
vs Industry
46
Median 3Y
7.9
Median 5Y
10
Industry
13.7
Forward
5.6
More Details
7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
7
vs History
77
vs Industry
43
Median 3Y
8.3
Median 5Y
12.1
Industry
17.2
Forward
6.7
More Details
7.4
EV/OCF
EV/OCF
Enterprise Value to OCF
7.4
vs History
80
vs Industry
45
Median 3Y
9
Median 5Y
10.7
Industry
16.5
More Details
9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
9
vs History
82
vs Industry
33
Median 3Y
10.7
Median 5Y
14.5
Industry
19.3
More Details
0.9
EV/IC
EV/IC
Enterprise Value to IC
0.9
vs History
80
vs Industry
66
Median 3Y
1.2
Median 5Y
1.5
Industry
2
More Details

Multiples Across Competitors

Competitors Multiples
Sino Biopharmaceutical Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
HK
Sino Biopharmaceutical Ltd
HKEX:1177
61.4B HKD 2.1 13.9 6 7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
746.8B USD 18.3 89.2 48 53.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.4 27.8
US
Johnson & Johnson
NYSE:JNJ
365.6B USD 4.2 24.9 12 15.7
US
Merck & Co Inc
NYSE:MRK
249.1B USD 3.9 20.5 10.4 12.4
CH
Roche Holding AG
SIX:ROG
208.6B CHF 3.6 18.1 10.2 12.1
CH
Novartis AG
SIX:NOVN
181.4B CHF 4.2 12.6 10 14.8
UK
AstraZeneca PLC
LSE:AZN
159.6B GBP 4.1 31.4 169.3 253.8
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
HK
Sino Biopharmaceutical Ltd
HKEX:1177
Average P/E: 30.7
13.9
56%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
89.2
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
24.9
-22%
US
Merck & Co Inc
NYSE:MRK
20.5
7 336%
CH
Roche Holding AG
SIX:ROG
18.1
32%
CH
Novartis AG
SIX:NOVN
12.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.4
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 198,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.